SIRT6 and type 2 diabetes mellitus: Similarly, other SIRT6 activators, such as fucoidan, MDL-800, quercetin, luteolin, pyrrolo-[1,2-a]quinoxaline analogs may be assessed preclinically for the therapeutic potential to correct metabolic abnormalities in T2DM [206].